Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data

Autor: Inger Johansson, Renee Baak-Pablo, Birgit A. L. M. Deiman, William G. Allard, Maaike van der Lee, Patrick Neven, Magnus Ingelman-Sundberg, Henk-Jan Guchelaar, Rolf H. A. M. Vossen, Jesse J. Swen, Maarten J. Deenen, Seyed Yahya Anvar, Roberta Menafra, Stefano Gastaldello

Publikováno v: Science Translational Medicine, 13(603). AMER ASSOC ADVANCEMENT SCIENCE
Science Translational Medicine, 13(603):eabf3637. American Association for the Advancement of Science (AAAS)
Science Translational Medicine

Pharmacogenomics is a key component of personalized medicine that promises safer and more effective drug treatment by individualizing drug choice and dose based on genetic profiles. In clinical practice, genetic biomarkers are used to categorize pati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f0664d95ca1b3b663344e2cce145d90
https://hdl.handle.net/1887/3209082

The variant T allele of PvuII in ESR1 gene is a prognostic marker in early breast cancer survival

Autor: Henk-Jan Guchelaar, Judith R. Kroep, Danny Houtsma, Caroline M. Seynaeve, Renee Baak-Pablo, Cornelis J.H. van de Velde, Stefan Böhringer, Hans Gelderblom, Stefanie de Groot, Elma Meershoek – Klein Kranenbarg

Publikováno v: Scientific Reports
Scientific Reports, 11(1). NATURE RESEARCH
Scientific Reports, 11(1):3249. Nature Publishing Group
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)

The PvuII (rs2234693) Single Nucleotide Polymorphism (SNP) in the gene coding for the estrogen receptor-1 (ESR1), has been found associated with outcome in tamoxifen treated patients with early hormone-receptor positive breast cancer. However, it rem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4e4cfbf257d51688bec7d85a339241
https://doi.org/10.1038/s41598-021-82002-z

Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial

Autor: Elma Meershoek-Klein Kranenbarg, Hans Gelderblom, Danny Houtsma, Hein Putter, Renee Baak-Pablo, Cornelis J.H. van de Velde, Caroline Seynaeve, D.B.Y. Fontein, Johan W. R. Nortier, Henk-Jan Guchelaar, Tahar van der Straaten

Publikováno v: Breast Cancer Research and Treatment, 144(3), 599-606
Breast Cancer Research and Treatment, 144(3), 599-606. Springer New York

Musculoskeletal adverse events (MSAEs) and vasomotor symptoms (VMSs) are known side-effects of aromatase inhibitors, and may be related to genetic variations of the aromatase gene (CYP19A1). We investigated the relationship between these specific AEs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2273b449cb646eaa09e63663c7a49a1
https://pure.eur.nl/en/publications/ea5e0ca9-f1f2-44e3-ba08-4b1c3092f576

Association of ABCB1, 5-HT3B Receptor and CYP2D6 Genetic Polymorphisms with Ondansetron and Metoclopramide Antiemetic Response in Indonesian Cancer Patients Treated with Highly Emetogenic Chemotherapy

Autor: Henk-Jan Guchelaar, Judith A.M. Wessels, Johann W.R. Nortier, Robert J.H.M. van der Straaten, Mustofa Mustofa, Mohammad Hakimi, Renee Baak-Pablo, Hans Gelderblom, Dyah Aryani Perwitasari

Publikováno v: Japanese Journal of Clinical Oncology, 41(10), 1168-1176

Objective: Suboptimal treatment of chemotherapy-induced nausea and vomiting and unsatisfactory response to antiemetic drugs cause impairment of cancer patient’s daily functioning. This study was aimed to investigate the association of selected germ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5c3158abf32d7b51df6e1a0da502f00
https://doi.org/10.1093/jjco/hyr117

Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity

Autor: Ron H.J. Mathijssen, John B. A. G. Haanen, An K.L. Reyners, Henk-Jan Guchelaar, Epie Boven, Astrid A.M. van der Veldt, Tahar van der Straaten, Karel Eechoute, Nielka P. van Erp, Renee Baak-Pablo, Judith A.M. Wessels, Hans Gelderblom

Publikováno v: Journal of Clinical Oncology, 27(26), 4406-4412. American Society of Clinical Oncology
Journal of Clinical Oncology, 27(26), 4406-4412. AMER SOC CLINICAL ONCOLOGY
van Erp, N P, Eechoute, K, van der Veldt, A A M, Haanen, JB, Reyners, A K L, Mathijssen, R H J, Boven, E, van der Straaten, T, Baak-Pablo, R F, Wessels, J A M, Guchelaar, H J & Gelderblom, H 2009, ' Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity ', Journal of Clinical Oncology, vol. 27, no. 26, pp. 4406-4412 . https://doi.org/10.1200/JCO.2008.21.7679

Purpose To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of toxicities: thrombocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome, and any toxicity according to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bca489675c42a7b290eb9bcaf1752202
https://doi.org/10.1200/JCO.2008.21.7679